See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
World Cup
Boxing
Elon Musk
WWE
Social Media
Donald Trump
Baseball
Natural Disasters
Eid
Cristiano Ronaldo
Artificial Intelligence
Soccer
Published • loading... • Updated

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

Summary by cancernetwork.com
Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
curetoday.comcuretoday.com

MVdeltaC Earns Orphan Drug Status for Pleural Mesothelioma

The FDA granted orphan drug designation to MVdeltaC, a measles virus-based immunotherapy, for pleural mesothelioma, supporting its future development.

Read Full Article
cancernetwork.comcancernetwork.com

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.

Read Full Article
targetedonc.comtargetedonc.com

BNT327/Chemo Shows Durable Responses in Mesothelioma

A novel bispecific antibody, BNT327/PM8002, shows promising efficacy in treating unresectable mesothelioma, combining well with chemotherapy for durable responses.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

targetedonc.com broke the news in on Thursday, June 5, 2025.
Sources are mostly out of (0)

Similar News Topics

News
For You
SearchBlindspotLocal